View all the latest information in
, arranged by trials and clinical studies. Listed below are recently added trial updates.
Real-world experience with ruxolitinib in myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...
How to switch therapies in patients with myelofibrosis
Myelofibrosis (MF) is a heterogeneous disease with limited treatment options, which may cause treatment challenges when patients no longer...
Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020
MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain...
ASH 2019 | MANIFEST phase II results: CPI-0610 BETi for refractory/intolerant myelofibrosis
During ASH 2019, John Mascarenhas presented an oral abstract1 on the interim results of MANIFEST. This...
Long-term safety analyses of momelotinib in patients with myelofibrosis
Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1)...
Review of novel agents for myeloproliferative neoplasms
In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with...
Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?
The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San...